Lv2
180 积分 2023-09-13 加入
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
7天前
已完结
New insights into the role of antinuclear antibodies in systemic lupus erythematosus
12天前
已完结
396P Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
1个月前
已完结
396P Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
1个月前
已关闭
Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody
1个月前
已完结
Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC)
4个月前
已关闭
中国干眼临床诊疗专家共识（2024年）
4个月前
已完结
中国干眼临床诊疗专家共识（2024年）
4个月前
已关闭
Abstract 1153: Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody
10个月前
已关闭
皖公网安备34019202002308
